Mode
Text Size
Log in / Sign up

Greater cognitive variability in NSD Stage 2 predicts progression to advanced stages in observational study

Greater cognitive variability in NSD Stage 2 predicts progression to advanced stages in observationa…
Photo by National Cancer Institute / Unsplash
Key Takeaway
Consider cognitive variability as a potential progression marker in NSD, pending replication.

This observational analysis used data from 934 participants in the Parkinson's Progression Markers Initiative, including 832 individuals with Neuronal Synuclein Disease (NSD) Stage 2 and 102 healthy controls. The study quantified intraindividual variability/dispersion (IIV-D) using total coefficient of variation (CoV) and domain-specific attention/executive CoV to examine group differences and predictive value for disease progression.

Stage 2 participants exhibited significantly greater total CoV than healthy controls (p = .003). Higher IIV-D was associated with worse motor symptoms, non-motor burden, and functional impairment. Among Stage 2 participants, the 100 individuals who subsequently converted to Stage 3+ had significantly higher total CoV and attention/executive CoV at baseline compared to non-converters (total CoV p = .008; attention/executive CoV p = .020). After controlling for baseline motor severity, CoV independently predicted conversion to Stage 3+ after one year (OR = 1.44, p = .008).

No safety or tolerability data were reported for this cognitive assessment. The authors note that replication is needed to confirm generalizability and clinical utility. As an observational study, these findings show association, not causation. The results support further investigation of cognitive dispersion metrics for early detection strategies in prodromal synucleinopathies, but should not yet guide clinical decision-making without validation.

Study Details

Sample sizen = 100
EvidenceLevel 5
PublishedMar 2026
View Original Abstract ↓
BackgroundNeuronal synuclein disease (NSD) involves pathological -synuclein presence and often dopaminergic dysfunction, initially preceding overt clinical symptoms. NSD-ISS identifies Stage 2A (no dopaminergic dysfunction) and 2B (dopaminergic dysfunction) as prodromal phases marked by subtle clinical signs without functional impairment. Intraindividual variability/ dispersion (IIV-D), reflecting within-person inconsistency across cognitive tasks, has emerged as a potential marker of early neurodegenerative changes. ObjectivesThis study examined whether IIV-D differentiates NSD Stage 2 participants from healthy controls and predicts progression to more advanced NSD stages. MethodsData from the Parkinsons Progression Markers Initiative were used to assess performance across 11 neuropsychological tests in 934 participants (832 Stage 2; 102 controls). IIV-D was quantified using the total coefficient of variation (CoV) and a domain-specific attention/executive CoV. Group comparisons and logistic regression assessed associations between IIV-D, clinical characteristics, and disease progression. ResultsStage 2 participants exhibited significantly greater CoV than controls (p = .003). Higher IIV-D was associated with worse motor symptoms, non-motor burden, and functional impairment. Among Stage 2 participants, subsequent converters to Stage 3+ (n = 100) had significantly higher total CoV (p = .008) and attention/executive CoV (p = .020) at baseline. CoV independently predicted conversion after one year (OR = 1.44, p = .008), controlling for baseline motor severity. ConclusionsIIV-D, particularly CoV, may be a sensitive cognitive marker of early NSD and predict short-term disease progression. Findings support integrating cognitive dispersion metrics into early detection strategies for prodromal synucleinopathies, though replication is needed to confirm generalizability and clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.